Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number			10698321			
	Filing Date			2003-10-31		
	First Named Inventor Jos ve		van den Bogerd			
	Art Unit		1711			
	Examiner Name	Irina :	Sopjia Zemel			
	Attorney Docket Number		143766-1	_		

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear					
	1	5712332		1998-01	1-27	Kaleda et al					
If you wisl	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPL	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	ber Kind Publication Name of Patentee of cited Document			Releva		Lines where ges or Relev			
	1										
	ľ										
If you wis	·	dd additional U.S. Publi	shed Ap	plication	n citatio	n information p	please click the Ad	ld button	Add		
If you wis	·	d additional U.S. Publi		,		n information p		ld button	Add		
	h to a	d additional U.S. Publi Foreign Document Number ³		FORE		Publication		e or F	Remove ages,Col	lumns,Lines evant or Relevant	т.
Examiner	h to a	Foreign Document	Country	FORE	SN PA1	Publication	Name of Patente	e or F	Remove Pages,Col where Rel Passages	lumns,Lines evant or Relevant	T5
Examiner	Cite No	Foreign Document Number ³	Country Code ²	FORE	Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or F	Remove Pages,Col where Rel Passages	lumns,Lines evant or Relevant	T ⁵
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² EP	FOREK	Kind Code ⁴	Publication Date 2006-11-22	Name of Patente Applicant of cited Document Van den Bogert Gallego et al	e or F	Remove Pages,Col where Rel Passages	lumns,Lines evant or Relevant	т.

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţ5	
	1	European Search Report, Infernational Application No. PCTA/S20060225870, Applicant's File Reference No 08CS181519; International Filing date 2006-06-30; Date of Mailing 2007-02-01; 5 pages		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTIO Patent Documents at year LISPTIO, CODE or MEPE 901.6.2 Editor office that issued the document, by the holietier code (WIPO Standard ST.3). 3 For disparsee patent obcuments, by the indication of the year of the Propriet many percectible seed number of the Pederal concurrent, "I find of coursent by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if Expolite Improaces the relation to a standard.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10698321
Filing Date			2003-10-31
First Named Inventor Jos va		Jos v	an den Bogerd
Art Unit			1711
	Examiner Name Irina		Sopjia Zemel
	Attorney Docket Numb	er	143766-1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c).

1	See	attached	certification	statement.	

		guhmitted berewith

▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

on de signature.							
Signature	/David E. Rodrigues/	Date (YYYY-MM-DD)	2007-03-20				
Name/Print	David F. Rodrigues	Registration Number	50604				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.